Largest pharmaceutical companies in the world: the top 20 by 2025 revenue

This list is for people who sell to drugmakers: clinical research and patient recruitment services, lab and manufacturing suppliers, validation and quality consultants, packaging and logistics firms, marketing agencies and software vendors. It ranks the 20 largest pharmaceutical companies by revenue from their own 2025 filings, shows how the order changes when you count medicines only, counts the US industry from Census data, and explains where the buying happens inside companies this size.

The 20 largest pharmaceutical companies by revenue

Revenue as reported in each company's latest annual report (Form 10-K, Form 20-F or, for companies that don't file with the SEC, the published annual report or results release), checked on 30 October 2026.

Dollar conversions use the Federal Reserve's 2025 annual average rates (G.5A, released 5 January 2026): CHF 0.8305, DKK 6.6137 and ¥149.5686 per dollar; $1.1306 per euro and $1.3192 per pound. Takeda's year ended 31 March 2026, so its conversion is an approximation. Regeneron ($14.34 billion) is just ahead of Viatris ($14.30 billion).

Three things to keep in mind when you read it:

• Two totals include more than medicines. J&J's $94.2 billion includes $33.8 billion of MedTech sales; its Innovative Medicine segment sold $60.4 billion. Roche's total includes CHF 13.8 billion from its Diagnostics Division.
• Growth has split the field. Lilly's revenue rose from $45.0 billion in 2024 to $65.2 billion, driven mainly by Mounjaro and Zepbound, according to its 10-K. Novo Nordisk's sales grew 6% in Danish kroner (10% at constant exchange rates), and it let about 9,000 employees go in a restructuring during the year.
• Headcount definitions differ. J&J counts full-time and part-time employees (its full-time equivalent figure is 138,200), Novartis reports full-time equivalents, and GSK's annual report gives the average for the year.

Ranked by prescription medicines only

If you sell into drug development, manufacturing or commercial teams, the medicines figure matters more than the group total. Using the segments each company reports:

On this basis the top seven sit within $8 billion of each other, which is why rankings that use slightly different measures or exchange rates disagree so often.

How this list is built

• What's counted. Total revenue (or net sales) as reported in the consolidated income statement for the latest fiscal year filed by 30 October 2026, including all consolidated subsidiaries. We opened each filing rather than relying on tagged data, because tags vary between companies.
• Currencies. Six companies report in Swiss francs, euros, Danish kroner, pounds or yen. We show the reported figure first and a dollar conversion at the 2025 average rate. A different rate (year-end, or each quarter's average) would move the converted figures by a few percent and could swap close neighbors.
• Who's left out. Groups where medicines are well under half of revenue, such as Bayer (crop science) and Abbott ($44.3 billion of devices, diagnostics, nutrition and established medicines in 2025). Drug distributors and pharmacy chains, which are larger by revenue but don't make medicines: see the largest healthcare companies. Private companies that don't publish results; Boehringer Ingelheim is private but publishes, so it's in.
• Other lists. Fortune's Global 500, Forbes' Global 2000 and trade rankings such as Pharmaceutical Executive's annual Pharma 50 use other measures (prescription sales, market value, a blend). We didn't copy them; use them as a cross-check.
• Why not market cap. Market value moves every trading day and reflects expected future sales. Revenue is what a company actually earned and, roughly, what it has to spend with suppliers.

How many pharmaceutical companies there are in the US

County Business Patterns, the Census Bureau's count of business locations with paid employees, gives the US footprint for 2023. It counts establishments (plants, labs and offices), not companies, and classifies each by its main activity.

Most establishments are small: 369 of the 1,436 pharmaceutical preparation sites have fewer than five employees, and only 72 have 500 or more (53 with 500 to 999 and 19 with 1,000 or more). The large sites are where most of the spending on equipment, validation, quality and logistics happens. California has the most establishments (215), followed by New Jersey (125), Florida (104), New York (102), Texas (82), Massachusetts (75), Pennsylvania (57) and Utah (44).

Types of drugmaker and what each buys

For the companies just below this cut, see the largest biotech companies; Biogen ($9.9 billion) and Zoetis ($9.5 billion, animal health) would be next.

Where the buying happens at companies this size

The filings show how the work is divided, and each division has its own budget holders:

• Research and development. Merck reported about 24,700 people in research, Lilly about 12,000 in R&D and Sanofi 9,274. Clinical operations and development teams choose contract research organizations, trial sites, recruitment vendors and data platforms, usually through a preferred-supplier list managed with procurement.
• Manufacturing and supply. Regeneron's 10-K puts 6,717 of its 15,410 full-time employees in industrial operations and product supply. Site heads, engineering and quality leaders decide on equipment, maintenance, validation and many services at the plant, inside a global quality system.
• Commercial. Novartis reported 17,491 full-time equivalent field force employees. Brand and marketing teams by therapy area buy agency, events, data and training work.
• Procurement. Category managers run sourcing events, supplier qualification and master agreements. Expect a quality agreement and audit before anything that touches a regulated process.

General guidance, not taken from any one company's policies: a first deal usually comes through one site or one brand team, with procurement joining once the scope is clear. Plan for supplier qualification to take months.

Worked example: a validation services firm in New Jersey and Pennsylvania

Illustrative example. The company, its prices and its conversion rates are invented; the establishment counts come from County Business Patterns 2023.

The seller: Calibra Validation (calibra.example), a 40-person firm that qualifies equipment and cleanrooms for regulated manufacturing. The goal: a year's pipeline from pharmaceutical sites near its base.

1. Size the area. New Jersey (125) and Pennsylvania (57) have 182 pharmaceutical preparation establishments between them.
2. Estimate the sites worth a visit. Nationally, 335 of the 1,436 establishments (23%) have 100 or more employees. Applying that share gives about 42 larger sites in the two states. Treat this as an estimate; the state files don't publish every size band.
3. Name them. Start with the owners in the table above that list New Jersey or Pennsylvania sites in their 10-K property sections, then fill in mid-size and private manufacturers.
4. Find the decision makers. For each site, the head of quality, the validation or engineering manager and the site head.
5. Do the arithmetic. If Calibra reaches the right person at 60% of the 42 sites, that's 25 conversations. If one in five starts a supplier qualification, that's 5, and at an assumed $180,000 a year per site, a $900,000 pipeline.

At this volume, matching sites to the right quality and engineering leads is the slow part; Bebop researches each account in a list and writes a playbook for it, with the people to contact and the angle to open with.

Subject: Equipment qualification at [site or city]

Hi [first name],

I saw [company] is [expanding / adding a line / hiring validation engineers] at the [site or city] site.

When a site adds capacity, quality teams often tell us the bottleneck is qualification paperwork, not the equipment itself.

We qualify equipment and cleanrooms for regulated manufacturers in New Jersey and Pennsylvania, and our documentation package is ready for your supplier review. Would 20 minutes be useful to see whether we'd fit your approved-vendor process?

[Your name]
[Phone number]

Common mistakes

• Ranking by market cap and calling it size. It changes daily and says little about spending.
• Mixing currencies without saying so. Always show the reported figure and the rate you used.
• Selling to headquarters when the site buys. Plant-level services are usually decided at the plant.
• Skipping qualification. Without quality documents ready, a good first meeting stalls.

Next step: see how many drugmakers operate in one state in the New Jersey pharmaceutical market report.